Company intelligence / Profile preview

RadaHaim

Seongnam-si, Gyeonggi-do, South Korearadahaim.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

RadaHaim specializes in the scalable production of human organoids—3D tissue models that closely mimic human physiology. Their proprietary platform addresses standardization challenges in organoid generation, enabling more reliable high-throughput screening for drug toxicity and efficacy. This supports advances in both general drug development pipelines and personalized medicine approaches. No clinical results reported as they are a research tools/platform provider.

Modalities: Organoid-based assayHigh-throughput screening platform
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on RadaHaim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RadaHaim.

Explore the full profile